Needham analyst Ami Fadia reaffirmed a Buy rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and raised the price target ...

Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

The medium-sized biopharma is showing off new results from dordaviprone and Zepzelca, both of which were acquired through ...